- The FDA has accepted for review Merck's (MRK) biologics license application for V503, a vaccine for human papillomavirus (HPV), a sexually transmitted virus that can cause cervical and other cancer.
- V503 is designed to provide protection against the four HPV strains that Merck's Gardasil protects against plus five additional cancer-causing types of the virus. Trial data appears to support the new vaccine's efficacy. (PR)
FDA accepts Merck HPV vaccine for review
Feb 20 2014, 09:13 ET